Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Medexus Pharmaceuticals
MDP
Medexus Pharmaceuticals
Regulatory Pressure Will Limit Revenues While Allowing Cautious Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
26 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$5.55
48.6% undervalued
intrinsic discount
16 Aug
CA$2.85
Loading
1Y
15.9%
7D
8.0%
Author's Valuation
CA$5.6
48.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$5.6
48.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-31m
223m
2014
2017
2020
2023
2025
2026
2028
Revenue US$222.9m
Earnings US$33.4m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
11.62%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
US$33.42m
Earnings '28
x
10.14x
PE Ratio '28
=
US$338.82m
Market Cap '28
US$338.82m
Market Cap '28
/
70.87m
No. shares '28
=
US$4.78
Share Price '28
US$4.78
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
US$4.02
Fair Value '25
US$4.02
Fair Value '25
Converted to CAD @ 1.3814 USD/CAD Exchange Rate
=
CA$5.55
Fair Value '25
